ArticleFrontiers in oncology2022
Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence in predicting recurrence after first-line treatment of liver cancer: a systematic review and meta-analysis.BMC medical imaging · 2024Pooled it
- Artificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives.Discover oncology · 2025Review
- Leveraging deep learning to discover interpretable cellular spatial biomarkers for prognostic predictions based on hepatocellular carcinoma histology.The journal of pathology. Clinical research · 2025Article
- Advances and challenges in pathomics for liver cancer: From diagnosis to prognostic stratification.World journal of clinical oncology · 2025Review
- Deep learning-based interpretable prediction of recurrence of diffuse large B-cell lymphoma.BJC reports · 2025Article
- Deep Learning Radiopathomics Models Based on Contrast-enhanced MRI and Pathologic Imaging for Predicting Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma.Radiology. Imaging cancer · 2025Article
- Article
- Review
- Identifying immune infiltration by deep learning to assess the prognosis of patients with hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Recent Advancements in Deep Learning Using Whole Slide Imaging for Cancer Prognosis.Bioengineering (Basel, Switzerland) · 2023Review
- Artificial Intelligence-Based Opportunities in Liver Pathology-A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Recent advances in recurrent hepatocellular carcinoma therapy.World journal of hepatology · 2023Review
- Perioperative predictors of outcome of hepatectomy for HBV-related hepatocellular carcinoma.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative recurrence impedes the curability of early-stage hepatocellular carcinoma (E-HCC). We aimed to establish a novel recurrence-related pathological prognosticator with artificial intelligence, and investigate the relationship between pathological features and the local immunological microenvironment. Methods: A total of 576 whole-slide images (WSIs) were collected from 547 patients with E-HCC in the Zhongshan cohort, which was randomly divided into a training cohort and a validation cohort. The external validation cohort comprised 147 Tumor Node Metastasis (TNM) stage I patients from The Cancer Genome Atlas (TCGA) database. Six types of HCC tissues were identified by a weakly supervised convolutional neural network. A recurrence-related histological score (HS) was constructed and validated. The correlation between immune microenvironment and HS was evaluated through extensive immunohistochemical data. Results: The overall classification accuracy of HCC tissues was 94.17%. The C-indexes of HS in the training, validation and TCGA cohorts were 0.804, 0.739 and 0.708, respectively. Multivariate analysis showed that the HS (HR= 4.05, 95% CI: 3.40-4.84) was an independent predictor for recurrence-free survival. Patients in HS high-risk group had elevated preoperative alpha-fetoprotein levels, poorer tumor differentiation and a higher proportion of microvascular invasion. The immunohistochemistry data linked the HS to local immune cell infiltration. HS was positively correlated with the expression level of peritumoral CD14 Conclusions: The study established a novel histological score that predicted short-term and long-term recurrence for E-HCCs using deep learning, which could facilitate clinical decision making in recurrence prediction and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.